BTS SPA

BTS SPA specializes in biomechanical analysis systems, particularly those focused on motion-tracking and gait assessment. Their portfolio also includes electromyography (EMG) devices, which measure muscle activity and jaw movement. Examples include motion-tracking systems like TMJOINT and P6000, as well as EMG solutions such as FREEEMG, OMNisEMG, and TEETHAN. These devices are designed for clinical and research applications, often incorporating wearable or modular technology.

BTS SPA operates from the United States, which means their devices must comply with FDA regulations. The FDA classifies their products as either Class I or Class II, depending on risk factors like intended use and potential patient harm. Since the company is based in the US, their devices are subject to FDA oversight, including registration, listing, and UDI requirements, ensuring they meet regulatory standards for safety and performance.

Yes, BTS SPA’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This listing is important because it provides transparency in the medical device supply chain, helping healthcare providers, regulators, and manufacturers track devices throughout their lifecycle. The UDI system ensures accurate identification, reduces medical errors, and supports compliance with FDA regulations.

The FDA classifies BTS SPA’s devices as either Class I or Class II. Class I devices generally pose minimal risk and are subject to general controls, while Class II devices require additional regulations due to moderate risk. The classification depends on factors like the device’s intended use, potential harm to patients, and the level of scrutiny needed to ensure safety and effectiveness. For example, motion-tracking systems like TMJOINT may fall into Class II if they involve higher-risk applications.